메뉴 건너뛰기




Volumn 12, Issue 8, 2013, Pages 1429-1441

Strengthening context-dependent anticancer effects on non-small cell lung carcinoma by inhibition of both MET and EGFR

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; SCATTER FACTOR RECEPTOR; SGX 523; UNCLASSIFIED DRUG;

EID: 84882245425     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0016     Document Type: Article
Times cited : (21)

References (31)
  • 1
    • 0034644539 scopus 로고    scopus 로고
    • Cell signaling by receptor tyrosine kinases
    • Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103:211-25.
    • (2000) Cell , vol.103 , pp. 211-225
    • Schlessinger, J.1
  • 2
    • 0035902180 scopus 로고    scopus 로고
    • Oncogenic kinase signalling
    • Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001;411:355-65.
    • (2001) Nature , vol.411 , pp. 355-365
    • Blume-Jensen, P.1    Hunter, T.2
  • 3
    • 2342591455 scopus 로고    scopus 로고
    • The discovery of receptor tyrosine kinases: Targets for cancer therapy
    • Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: Targets for cancer therapy. Nat Rev Cancer 2004;4:361-70.
    • (2004) Nat Rev Cancer , vol.4 , pp. 361-370
    • Gschwind, A.1    Fischer, O.M.2    Ullrich, A.3
  • 4
    • 79952284127 scopus 로고    scopus 로고
    • Hallmarks of cancer: The next generation
    • Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144:646-74.
    • (2011) Cell , vol.144 , pp. 646-674
    • Hanahan, D.1    Weinberg, R.A.2
  • 6
    • 84882289352 scopus 로고    scopus 로고
    • American Cancer Society. Cancer facts and figures 2010. Atlanta, GA: American Cancer Society; 2010
    • American Cancer Society. Cancer facts and figures 2010. Atlanta, GA: American Cancer Society; 2010.
  • 7
    • 52249116587 scopus 로고    scopus 로고
    • EGFR-targeted therapeutics: Focus on SCCHN and NSCLC
    • Sattler M, Abidoye O, Salgia R. EGFR-targeted therapeutics: Focus on SCCHN and NSCLC. Sci World J 2008;8:909-19.
    • (2008) Sci World J , vol.8 , pp. 909-919
    • Sattler, M.1    Abidoye, O.2    Salgia, R.3
  • 9
    • 77958478674 scopus 로고    scopus 로고
    • Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
    • Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010;10: 760-74.
    • (2010) Nat Rev Cancer , vol.10 , pp. 760-774
    • Pao, W.1    Chmielecki, J.2
  • 10
    • 34249075147 scopus 로고    scopus 로고
    • MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
    • Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43.
    • (2007) Science , vol.316 , pp. 1039-1043
    • Engelman, J.A.1    Zejnullahu, K.2    Mitsudomi, T.3    Song, Y.4    Hyland, C.5    Park, J.O.6
  • 12
    • 38049150665 scopus 로고    scopus 로고
    • MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
    • Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007;104:20932-7.
    • (2007) Proc Natl Acad Sci U S A , vol.104 , pp. 20932-20937
    • Bean, J.1    Brennan, C.2    Shih, J.Y.3    Riely, G.4    Viale, A.5    Wang, L.6
  • 13
    • 84855543629 scopus 로고    scopus 로고
    • EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers
    • Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A, et al. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 2012;18:74-82.
    • (2012) Nat Med , vol.18 , pp. 74-82
    • Garofalo, M.1    Romano, G.2    Di Leva, G.3    Nuovo, G.4    Jeon, Y.J.5    Ngankeu, A.6
  • 15
    • 64849102583 scopus 로고    scopus 로고
    • Role of c-Met in cancer: Emphasis on lung cancer
    • Salgia R. Role of c-Met in cancer: Emphasis on lung cancer. Semin Oncol 2009;36:S52-8.
    • (2009) Semin Oncol , vol.36
    • Salgia, R.1
  • 16
    • 78649420006 scopus 로고    scopus 로고
    • MET signalling: Principles and functions in development, organ regeneration and cancer
    • Trusolino L, Bertotti A, Comoglio PM. MET signalling: Principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010;11:834-48.
    • (2010) Nat Rev Mol Cell Biol , vol.11 , pp. 834-848
    • Trusolino, L.1    Bertotti, A.2    Comoglio, P.M.3
  • 18
    • 36849065315 scopus 로고    scopus 로고
    • Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
    • Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-203.
    • (2007) Cell , vol.131 , pp. 1190-1203
    • Rikova, K.1    Guo, A.2    Zeng, Q.3    Possemato, A.4    Yu, J.5    Haack, H.6
  • 21
    • 76749157917 scopus 로고    scopus 로고
    • Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency
    • McDermott U, Pusapati RV, Christensen JG, Gray NS, Settleman J. Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. Cancer Res 2010;70:1625-34.
    • (2010) Cancer Res , vol.70 , pp. 1625-1634
    • McDermott, U.1    Pusapati, R.V.2    Christensen, J.G.3    Gray, N.S.4    Settleman, J.5
  • 22
    • 77956296140 scopus 로고    scopus 로고
    • MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth
    • Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R, et al. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res 2010;70:6880-90.
    • (2010) Cancer Res , vol.70 , pp. 6880-6890
    • Zhang, Y.W.1    Staal, B.2    Essenburg, C.3    Su, Y.4    Kang, L.5    West, R.6
  • 23
    • 19944430738 scopus 로고    scopus 로고
    • Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor
    • Zhang YW, Su Y, Lanning N, Gustafson M, Shinomiya N, Zhao P, et al. Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor. Oncogene 2005;24:101-6.
    • (2005) Oncogene , vol.24 , pp. 101-106
    • Zhang, Y.W.1    Su, Y.2    Lanning, N.3    Gustafson, M.4    Shinomiya, N.5    Zhao, P.6
  • 24
    • 0021118703 scopus 로고
    • Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
    • Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
    • (1984) Adv Enzyme Regul , vol.22 , pp. 27-55
    • Chou, T.C.1    Talalay, P.2
  • 25
    • 33947207989 scopus 로고    scopus 로고
    • Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival
    • Lutterbach B, Zeng Q, Davis LJ, Hatch H, Hang G, Kohl NE, et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res 2007;67:2081-8.
    • (2007) Cancer Res , vol.67 , pp. 2081-2088
    • Lutterbach, B.1    Zeng, Q.2    Davis, L.J.3    Hatch, H.4    Hang, G.5    Kohl, N.E.6
  • 26
    • 73149091443 scopus 로고    scopus 로고
    • SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo
    • Buchanan SG, Hendle J, Lee PS, Smith CR, Bounaud PY, Jessen KA, et al. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. Mol Cancer Ther 2009;8:3181-90.
    • (2009) Mol Cancer Ther , vol.8 , pp. 3181-3190
    • Buchanan, S.G.1    Hendle, J.2    Lee, P.S.3    Smith, C.R.4    Bounaud, P.Y.5    Jessen, K.A.6
  • 27
    • 80052511675 scopus 로고    scopus 로고
    • Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC
    • (suppl; abstr 7505)
    • Spigel DR, Ervin TJ, Ramlau R, Daniel DB, Goldschmidt JH, Blumenschein GR, et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol 29: 2011 (suppl; abstr 7505).
    • (2011) J Clin Oncol , vol.29
    • Spigel, D.R.1    Ervin, T.J.2    Ramlau, R.3    Daniel, D.B.4    Goldschmidt, J.H.5    Blumenschein, G.R.6
  • 28
    • 80051974548 scopus 로고    scopus 로고
    • Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer
    • Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011;29:3307-15.
    • (2011) J Clin Oncol , vol.29 , pp. 3307-3315
    • Sequist, L.V.1    Von Pawel, J.2    Garmey, E.G.3    Akerley, W.L.4    Brugger, W.5    Ferrari, D.6
  • 29
    • 62549161686 scopus 로고    scopus 로고
    • Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells
    • Agarwal S, Zerillo C, Kolmakova J, Christensen JG, Harris LN, Rimm DL, et al. Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells. Br J Cancer 2009;100: 941-9.
    • (2009) Br J Cancer , vol.100 , pp. 941-949
    • Agarwal, S.1    Zerillo, C.2    Kolmakova, J.3    Christensen, J.G.4    Harris, L.N.5    Rimm, D.L.6
  • 30
    • 84860214990 scopus 로고    scopus 로고
    • Intra-tumour heterogeneity: A looking glass for cancer?
    • Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: A looking glass for cancer? Nat Rev Cancer 2012;12:323-34.
    • (2012) Nat Rev Cancer , vol.12 , pp. 323-334
    • Marusyk, A.1    Almendro, V.2    Polyak, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.